Context Therapeutics, Inc. CNTX 深 滬
已收盤 08-07 16:00:00 美东时间
0.484
-0.020
-3.97%
華盛通- 最 高0.5287
- 今 開0.5099
- 成交量 242.72万股
- 最 低 0.48
- 昨 收 0.504
- 總市值 4446.95万
- 52周最高 3.62
- 市盈率 靜 --
- 換手率 2.64%
- 52周最低 0.48
- 委 比 99.82%
- 總股本 9187.92万
- 歷史最高 10.87
- 量 比 1.11
- 振 幅 9.66%
- 歷史最低 0.47
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move
Context Therapeutics Inc. (NASDAQ:CNTX) shares fell 30.45% in Wednesday’s after-hours session after the company reported its second-quarter financial results. The stock closed Wednesday’s regular session up 11.45% at $0.69 before falling 30.45% to $0.48 in after-hours trading. Context Therapeutics i...
08-06 13:32
Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 66.67 percent decrease over losses of $(0.09) per share from the same period last year.
08-06 06:04
Context Therapeutics Added To Russell 2000, Russell 3000 Indexes, Effective June 26
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000® and the broad-market Russell 3000® Inde...
07-07 04:08
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispecific Antibody, CTIM-76, In Advanced, Late-Line Platinum-Resistant Ovarian Cancer
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome ("CRS") in PROC limited to Grade 1 in 11% of patients Pharmacokinetic ("PK") profile supports exploration o...
06-15 18:33
Context Therapeutics Announces Amendment To Its Exclusive License Agreement With BioAtla To Remove All Future Milestone And Royalty Obligations For CT-202 In Exchange For A $4.5M Upfront Payment And A Final $2M Payment Due By August 1
Phase 1 initiation for CT-202 trial expected in third quarter of 2026
05-18 18:49
Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 80 percent decrease over losses of $(0.05) per share from
05-07 04:54
Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the U.S.
04-02 19:34
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7
Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.
03-24 20:59
